Stem cells can become a treatment for common joint disease

May 31, 2022

In the future, it is hoped that stem cells can be used to treat osteoarthritis, the world’s most common joint disease. Research is proceeding within a major European collaboration where the University of Gothenburg is one of the partners, according to a news release.

Within a large European research collaboration, work is underway to make it possible to use stem cells to rebuild cartilage tissue that has been worn out. The research collaboration, known as AutoCRAT, includes researchers at universities, research institutes, and companies in Ireland, Italy, the Netherlands, Sweden, and Germany.

Arthritis, or osteoarthritis as the disease is also called, is a chronic disease that affects one out of four Swedes over the age of 45. Treatment currently consists mainly of physiotherapy and pain relief, but there is no cure for the disease.

“In AutoCRAT we develop new stem cell-based products, all of which have the potential to become a future treatment. Soon we need to agree within the project on which alternative is most likely to become a cell therapy for osteoarthritis, which we will test next year in a large animal model.”

The first option being investigated in the EU project is mesenchymal stem cells, a type of adult stem cell taken from adipose tissue or bone marrow. Another track is induced pluripotent stem cells, IPS, which is a method of inducing adult cells to become stem cells again. These cells can then be reprogrammed into cartilage cells, which can provide large amounts of cells that could serve the need of many patients. The third track concerns what are known as extracellular vesicles. These vesicles are small spheres of biological information that separate from the surface of the cell. They act as messengers between cells and may control the growth of cartilage cells or reduce inflammation in joints.

“Our research team in Gothenburg has extensive clinical experience of cell therapy and has long been repairing cartilage. We assist the AutoCRAT project by providing cartilage cells that the end product can be compared with. We cultivate cartilage cells and examine their extracellular vesicles. For many years, we have developed new protocols where we differentiate IPS cells to become chondrocytes. In this way we hope to produce a universal donor for osteoarthritis patients.”

Anders Lindahl, a Professor at the University of Gothenburg and senior researcher in the EU project AutoCRAT, was one of the first in the world to start working with cell therapy. In the early 1990s, he and his colleagues began treating patients with cartilage damage with the patient’s own cells. That treatment has become an approved cell therapy, which thousands of patients have received. Unfortunately, this form of treatment only works for patients with an isolated cartilage injury where there is healthy cartilage available and where the patient can be their own cell donor.

“The protocol that we are developing describes in great detail how to handle the cells during the differentiation to achieve the desired result. The collaboration within AutoCRAT will then lead to optimal automatic production, where a cell culture robot replaces expensive laboratory premises and high personnel costs. The goal is to produce large amounts of cells and functional extracellular vesicles with a protocol that makes it possible to treat a large number of patients suffering from osteoarthritis,” says Lindahl.

Visit University of Gothenburg for more news